You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company's total revenues were $1.7 million, including $897,000 in commercial testing revenue. Its test volume was up 38 percent.
Biocept's Target Selector liquid biopsy platform is designed to analyze both circulating tumor cell and circulating tumor DNA biomarkers from a blood sample.
OHSU was granted the rights to offer Biocept's Target Selector liquid biopsy testing services in Oregon as part of the deal.
The company said it expects to net around $8.4 million, which it will use for working capital and general corporate purposes.
Catalyst will use Biocept's liquid biopsy platform to screen for cancer in patients in a clinical study of its rare disease drug Firdapse.
Ahead of a longer-term goal to develop IVD kits, the company has a plan this year to allow early-access customers to take on one aspect of testing in their own labs.
The firm was able to maintain a minimum closing bid price of at least $1 per share for at least 10 consecutive business days.
Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
Investigators will compare results using Biocept's platform in cerebrospinal fluid to current standard methods for diagnosing leptomeningeal metastases.